Market revenue in 2021 | USD 134.6 million |
Market revenue in 2030 | USD 251.5 million |
Growth rate | 7.2% (CAGR from 2021 to 2030) |
Largest segment | Biomarker assay development & validation |
Fastest growing segment | Flow cytometry |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biomarker Assay Development & Validation, Flow cytometry, Others( Biomarker immunoassays, Biomarker Assessment) |
Key market players worldwide | Eurofins Scientific SE, SGS AG, Charles River Laboratories International Inc, Labcorp Drug Development, Thermo Fisher Scientific Inc, Icon PLC, IQVIA Holdings Inc, Syneos Health, Intertek Group PLC, BioAgilytix Labs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker testing services market will help companies and investors design strategic landscapes.
Biomarker assay development & validation was the largest segment with a revenue share of 59.73% in 2024. Horizon Databook has segmented the U.S. biomarker testing services market based on biomarker assay development & validation, flow cytometry, others( biomarker immunoassays, biomarker assessment) covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. dominated the market in 2024, owing to several pharmaceutical and biotechnology companies and outsourcing firms. Besides, the demand for biomarker testing services is growing in the U.S. due to the increased demand for personalized medicine, emerging R&D activities, and growing research institutions' biomarker discovery and validation efforts.
Moreover, continuous innovation of drugs among biotechnology and pharmaceutical companies, growing remarkable advancements in cancer therapeutics, and increased development of personalized medicine are expected to provide growth opportunities for the market.
In addition, growing strategic initiatives by companies are also contributing to market growth. Furthermore, biopharmaceutical companies in the region increasingly rely more on biomarker testing services; hence, many companies opt for biomarker testing services dedicated to quality excellence, ensuring safe & efficient therapy supply on time, and focusing more on product innovation.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biomarker testing services market , including forecasts for subscribers. This country databook contains high-level insights into U.S. biomarker testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account